Exclusive: Roche tees up $3B+ for Shape's RNA editing platform, with the bold promise of 'one-time' cures for Alzheimer's, Parkinson's

Max Gelman

Senior Editor

Alzheimer’s and Parkinson’s are two of the toughest nuts to crack in biopharma. Many have tried to develop effective therapies and many have failed, leading …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Roche tees up $3B+ for Shape's RNA editing platform, with the bold promise of 'one-time' cures for Alzheimer's, Parkinson's

Max Gelman

Senior Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A

Ex­clu­sive: Roche tees up $3B+ for Shape's RNA edit­ing plat­form, with the bold promise of 'one-time' cures for Alzheimer's, Parkin­son's

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Exclusive: Roche tees up $3B+ for Shape's RNA editing platform, with the bold promise of 'one-time' cures for Alzheimer's, Parkinson's

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A